Open AccessTreatment Options for COVID-19–Related Guillain-Barré Syndrome
Author(s) -
Sogand Goudarzi,
Shooka Esmaeeli,
Juan D. Valencia,
Maegan E. Lu,
Riley R. Hales,
Corey R. Fehnel,
Christopher Conley,
Sadeq A. Quraishi,
Ala Nozari
Publication year - 2021
Publication title -
the neurologist/the neurologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.43
H-Index - 60
eISSN - 2331-2637
pISSN - 1074-7931
DOI - 10.1097/nrl.0000000000000342
Subject(s) - medicine , guillain barre syndrome , interquartile range , covid-19 , pediatrics , tocilizumab , intensive care medicine , disease , infectious disease (medical specialty)
Central nervous system complications are reported in an increasing number of patients with Coronavirus Disease 2019 (COVID-19). COVID-19-related Guillain-Barré syndrome (GBS) is of particular importance given its association with higher mortality rates and prolonged respiratory failure.